| Characteristic | African N = 1601 |
Asian N = 361 |
European N = 1921 |
Other/Admixed N = 61 |
p-value2 |
|---|---|---|---|---|---|
| Sex | 0.6 | ||||
| Male | 85/160 (53%) | 23/36 (64%) | 110/192 (57%) | 4/6 (67%) | |
| Female | 75/160 (47%) | 13/36 (36%) | 82/192 (43%) | 2/6 (33%) | |
| Age at diagnosis, years | 59 (51-66) | 62 (51-67) | 66 (57-73) | 58 (50-64) | <0.001 |
| Prior MGUS | 0.2 | ||||
| Yes | 48/142 (34%) | 8/32 (25%) | 72/170 (42%) | 2/5 (40%) | |
| No | 94/142 (66%) | 24/32 (75%) | 98/170 (58%) | 3/5 (60%) | |
| Diagnosis | 0.14 | ||||
| Amyloidosis | 18/159 (11%) | 8/36 (22%) | 12/192 (6.3%) | 0/6 (0%) | |
| MGUS | 14/159 (8.8%) | 4/36 (11%) | 21/192 (11%) | 1/6 (17%) | |
| MM | 116/159 (73%) | 22/36 (61%) | 137/192 (71%) | 4/6 (67%) | |
| Other | 0/159 (0%) | 0/36 (0%) | 2/192 (1.0%) | 0/6 (0%) | |
| POEMS | 4/159 (2.5%) | 1/36 (2.8%) | 1/192 (0.5%) | 0/6 (0%) | |
| SMM | 7/159 (4.4%) | 1/36 (2.8%) | 19/192 (9.9%) | 1/6 (17%) | |
| Bone marrow plasma cells, % | 25 (10-60) | 20 (10-45) | 30 (10-50) | 20 (20-80) | 0.7 |
| ISS stage at diagnosis | 0.6 | ||||
| I | 88/141 (62%) | 19/32 (59%) | 96/147 (65%) | 2/5 (40%) | |
| II | 32/141 (23%) | 6/32 (19%) | 35/147 (24%) | 2/5 (40%) | |
| III | 21/141 (15%) | 7/32 (22%) | 16/147 (11%) | 1/5 (20%) | |
| R-ISS stage | 0.084 | ||||
| I | 121/153 (79%) | 26/33 (79%) | 155/186 (83%) | 3/6 (50%) | |
| II | 9/153 (5.9%) | 2/33 (6.1%) | 7/186 (3.8%) | 2/6 (33%) | |
| III | 23/153 (15%) | 5/33 (15%) | 24/186 (13%) | 1/6 (17%) | |
| 1 n/N (%); Median (Q1-Q3) | |||||
| 2 Pearson’s Chi-squared test; Kruskal-Wallis rank sum test | |||||